Tenvir EM is used as part of a regiment of antiretroviral medications to treat HIV-1 in adults over 18. A single pill contains a combination of two anti-HIV drugs, emtricitabine and tenofovir disoproxil fumarate; however, Tenvir EM must be taken with at least one other anti-HIV medication to prevent HIV from progressing to AIDS.
Tenvir EM is taken orally once a day, at the same time every day, with or without food. Because Tenovir can cause renal impairment, patients with a creatinine clearance of 30 to 49 ml/min should only take one tablet every 48 hours, and patients with a creatinine clearance of less than 30 ml/min should not take Tenvir EM at all.
Patients hypersensitive to either emtricitabine or tenofovir disoproxil fumarate should not take Tenvir EM.
The most commonly reported side effects of Tenvir EM include:
Rarer side effects documented include:
Other adverse effects have been reported by patients taking Tenvir EM, so let your doctor know right away if you experience any health changes when beginning treatment.
Immune reconstitution syndrome may occur for a few weeks after a patient first starts taking Tenvir EM. Patients, especially those with previous renal impairments, should be monitored for evidence of toxicity and to ensure that the HIV viral load remains undetectable at regular intervals. Research on the safety and efficiency of Tenvir EM in patients with underlying liver disorders is inconclusive. Some patients with hepatitis B have experienced exacerbation of hepatitis symptoms after suddenly discontinuing Tenvir EM. Changes in distribution of body fat and bone structure have been linked to long term use of antiretroviral medications. Let your doctor know immediately if you notice any sudden changes in your body.
Tenvir EM can heighten the risk of renal complications in patients taking valacyclovir, valganciclovir, acyclovir, ganciclovir or cidofovir. Taking Tenvir EM with didanosine may exacerbate didanosine-associated side effects. Atazanavir and lopinavir/ritonavir can worsen Tenvir-associated side effects. Patients on Tenvir EM should never take atazanavir without also taking ritonavir.
Animal testing has shown no risk of birth defects when pregnant animals were administered Tenvir EM, but testing on pregnant humans has yet to be completed. Low concentrations of virus may be present in breast milk even when the patient is under treatment, so mothers infected with HIV are advised to avoid breastfeeding because of the potential to transmit the virus to their child.
Tenvir EM's ingredients can be toxic when taken in large doses, so seek medical treatment right away if you ingest more than the prescribed amount. A haemodialysis or a hemodialysis may be needed to purge the chemicals from the body.